UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

Breast cancer research : BCR, 2016-12, Vol.18 (1), p.126, Article 126

2016

Link zum Volltext

Verfügbarkeit prüfen

Pathological fracture from clinically occult breast cancer

The lancet oncology, 2021-03, Vol.22 (3), p.e131-e131

2021

Link zum Volltext

Verfügbarkeit prüfen

Amyotrophic Lateral Sclerosis in Northern Spain 40 Years Later: What Has Changed?

Neuro-degenerative diseases, 2016-09, Vol.16 (5-6), p.337-341

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

JNCI : Journal of the National Cancer Institute, 2008-06, Vol.100 (11), p.805-814

2008

Link zum Volltext

Verfügbarkeit prüfen

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2593-2599

2013

Link zum Volltext

Verfügbarkeit prüfen

Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer

Cancers, 2021-07, Vol.13 (14), p.3511

2021

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy

Acta radiologica (1987), 2015-11, Vol.56 (11), p.1300-1307

2015

Link zum Volltext

Verfügbarkeit prüfen

Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study

Clinical cancer research, 2003-02, Vol.9 (2), p.686-692

2003

Link zum Volltext

Verfügbarkeit prüfen

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

Scientific reports, 2019-12, Vol.9 (1), p.20081-12, Article 20081

2019

Link zum Volltext

Verfügbarkeit prüfen

The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.586-586

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-13-17: Impact on survival of primary tumor resection in women with de novo metastatic breast cancer. The GEICAM Alamo I-III breast cancer registry (1990-2001)

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P2-P2-13-17

2015

Link zum Volltext

Verfügbarkeit prüfen

A multicenter randomized phase II trial of granulocyte‐colony stimulating factor‐supported, platinum‐based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma

Cancer, 1998-08, Vol.83 (4), p.719-725

1998

Link zum Volltext

Verfügbarkeit prüfen

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study

Journal of clinical oncology, 2015-11, Vol.33 (32), p.3788-3795

2015

Link zum Volltext

Verfügbarkeit prüfen

Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

Expert review of pharmacoeconomics & outcomes research, 2013-06, Vol.13 (3), p.381-391

2013

Link zum Volltext

Verfügbarkeit prüfen

Quimioterapia complementaria tras una metastasectomía

Clinical & translational oncology, 2004-08, Vol.6 (6), p.372-373

López Vega, José Manual

2004

Link zum Volltext

Verfügbarkeit prüfen

Intravenous and Oral Magnesium Supplementations in the Prophylaxis of Cisplatin-Induced Hypomagnesemia

American journal of clinical oncology, 1992-08, Vol.15 (4), p.348-351

1992

Link zum Volltext

Verfügbarkeit prüfen

Carboplatin: an active drug in metastatic breast cancer

Journal of clinical oncology, 1992-03, Vol.10 (3), p.433-437

1992

Link zum Volltext

Verfügbarkeit prüfen

Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer

Clinical cancer research, 2003-02, Vol.9 (2), p.686

2003

Link zum Volltext

Verfügbarkeit prüfen

Comentarios acerca de un editorial relativo a vinflunina

Farmacia Hospitalaria, 2013-02, Vol.37 (1), p.77-77

2013

Link zum Volltext

Verfügbarkeit prüfen

Comments to an editorial on vinflunine

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2013-01, Vol.37 (1), p.77

2013

Link zum Volltext

Verfügbarkeit prüfen

Análisis farmacoeconómico del tratamiento de la deficiencia de hierro con hierro carboximaltosa (Ferinject®) en España

PharmacoEconomics. Spanish research articles, 2010-07, Vol.7 (3), p.109-117

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of mitonafide with a 3-day administration schedule : early interruption due to severe central nervous system toxicity

Investigational new drugs, 1994-01, Vol.12 (4), p.277-281

1994

Link zum Volltext

Verfügbarkeit prüfen

A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS653-TPS653

2012

Link zum Volltext

Verfügbarkeit prüfen

Central venous brachial catheter (P.A.S. port TM) and catheter scanning system (cath-finder TM)

Journal of surgical oncology, 1994-03, Vol.55 (3), p.190-193

1994

Link zum Volltext

Verfügbarkeit prüfen

Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.11107-11107

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(37)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Humans
(19)
Life Sciences & Biomedicine
(18)
Female
(16)
Middle Aged
(14)
Oncology
(14)
Aged
(12)
Adult
(11)
Breast Neoplasms - Drug Therapy
(10)
Breast Neoplasms - Pathology
(10)
Chemotherapy
(9)
Treatment Outcome
(9)
Biological And Medical Sciences
(8)
Breast Cancer
(8)
Medical Sciences
(8)
Tumors
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Drug Administration Schedule
(6)
Neoplasm Staging
(6)
Kaplan-Meier Estimate
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

Pathological fracture from clinically occult breast cancer

Amyotrophic Lateral Sclerosis in Northern Spain 40 Years Later: What Has Changed?

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study

Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer

Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy

Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis

Abstract P2-13-17: Impact on survival of primary tumor resection in women with de novo metastatic breast cancer. The GEICAM Alamo I-III breast cancer registry (1990-2001)

A multicenter randomized phase II trial of granulocyte‐colony stimulating factor‐supported, platinum‐based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study

Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

Quimioterapia complementaria tras una metastasectomía

Intravenous and Oral Magnesium Supplementations in the Prophylaxis of Cisplatin-Induced Hypomagnesemia

Carboplatin: an active drug in metastatic breast cancer

Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer

Comentarios acerca de un editorial relativo a vinflunina

Comments to an editorial on vinflunine

Análisis farmacoeconómico del tratamiento de la deficiencia de hierro con hierro carboximaltosa (Ferinject®) en España

Phase I study of mitonafide with a 3-day administration schedule : early interruption due to severe central nervous system toxicity

A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET)

Central venous brachial catheter (P.A.S. port TM) and catheter scanning system (cath-finder TM)

Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel

Suchergebnisse filtern